Kornimate/medical-research-clean huggingface dataset:
25g and 22g puncture needles

Conditions: Submucosal Tumor; Pancreas Tumor

Summary: the screened patients were randomly assigned 25g puncture needles and 22g puncture needles in a 1;1 ratio, based on the computer-generated random order, before receiving an ultrasound endoscope puncture. each puncture needle puncture lesions 2 needles, the same type of puncture needle tissue samples taken in the same tissue pathology bottle, all tissues after the completion of the necessary cytological smears, are placed in the formalin solution to send tissue pathology, pathologists do not know the order of distribution of 2 puncture needles to evaluate the tissue results, all pathology results are reported by the hospital pathology center, audit.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of real pancreatic swelling or submuscular swelling; * patients need to be guided by ultrasound endoscopy under the guidance of puncture to eliminate malignant lesions or clear lesions; * fully communicate before surgery, understand the risks and benefits of endoscopic operation, and sign an informed consent form. exclusion criteria: * there are endoscopic operation contraindications, including abnormal blood clotting, or long-term oral anticoagulant antiplatelet drugs, can not guarantee inr \< 1.5, or platelets less than 5 x 10 x 9 / l; * pregnant woman
umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis

Conditions: Liver Cirrhosis

Summary: this is a phase i, open label, single arm trial using uc-mscs to treat patients with liver cirrhosis that includes 20 patients. the primary outcome measure will be change in meld score at 3, 6, and 12 months after uc-msc transplantation from baseline. the safety is assessed by frequency and severity of the adverse event or serious adverse event associated with stem cell injection. this study could reconfirm the efficacy of stem cell transplantation for liver cirrhosis and would open a novel cell therapy for the treatment of adult liver cirrhosis.

liver cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands and causes by many forms of liver diseases and conditions such as hepatitis and chronic alcoholism. liver cirrhosis has become one of the major causes of morbidity and mortality with over one million people died due to cirrhosis in 2010 worldwide. currently, the only curative treatment for end-stage liver disease is liver transplantation. however, the shortage in donor organ availability and the side-effect associated with long-term immunosuppression after transplant requires the development of new alternative therapies for liver cirrhosis. recent clinical trials demonstrate that bone marrow-derived stem cells (bmdscs) as well as umbilical cord-derive mesenchymal stem cells (uc-mscs) improve liver function in patients with liver cirrhosis. in vietnam, however, there are no clinical trials to date that investigate the potential of uc-mscs for liver cirrhosis management. this is a phase i, open label, single arm trial using uc-mscs to treat patients with liver cirrhosis that includes 20 patients. the primary outcome measure will be change in meld score at 3, 6, and 12 months after uc-msc transplantation from baseline. the safety is assessed by frequency and severity of the adverse event or serious adverse event associated with stem cell injection. this study could reconfirm the efficacy of stem cell transplantation for liver cirrhosis and would open a novel cell therapy for the treatment of adult liver cirrhosis

Eligibility criteria:
inclusion criteria: * aged 18 to 70 years old. * patients diagnosed of liver cirrhosis: splenomegaly, elevated hepatic enzymes and/or esophageal varices detected by endoscopy, or liver biopsy demonstrated liver cirrhosis * be willing to complete the study and sign the consent form. exclusion criteria: * younger than 18 or older than 70 years old * recent infection * patients with history of chronic diseases such as cancer, chronic hepatitis, chronic kidney disease. * any clinically significant blood coagulation disorder(s)
establishment of tongue image database and machine learning model for malignant tumors diagnosis

Conditions: Malignant Tumor

Summary: the tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database. deep learning will be carried out by computer and artificial intelligence to construct the early screening, diagnosis, prognosis and prognosis model of various malignant tumors based on tongue image for the diagnosis and treatment of malignant tumors.


Eligibility criteria:
inclusion criteria: * 18≤age≤80 * histologically or cytologically confirmed malignant tumor * no prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for malignant tumor * subject volunteers to join the study, signs informed consent, has good compliance and can cooperate with follow-up exclusion criteria: * two or more kinds of malignant tumors at the same time * malignant tumor that has been treated by chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor therapy * subjects who had other factors that might force them to terminate the research ahead of time, such as the development of other severe disease (including mental disease) that required combined treatment, seriously abnormal laboratory examination value, and family or social factors that might affect the subject safety or experimental data collection, as judged by the researchers

Keywords: malignant tumor tongue image
epidemiological survey on metabolic dysfunction-associated fatty liver disease (mafld)

Conditions: Fatty Liver Disease

Summary: to investigate the prevalence of metabolic dysfunction-associated fatty liver disease (mafld) among adults in china

non-alcoholic fatty liver disease (nafld) is the most common chronic liver disease all over the world (1). in early 2020, a new definition of mafld has been proposed and is becoming increasingly widely accepted. the new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). the information on the prevalence of mafld is scarce. this study is designed to conduct mafld screening in adults with health check-ups at multiple health examination centers across china. the primary objective is to investigate the prevalence of mafld among adults in china.

Eligibility criteria:
inclusion criteria: * aged between 18 and 75, both sex; * able to sign informed consent. exclusion criteria: * pregnant women and those who are implanted with pacemakers, stents or any other metal devices.

Keywords: mafld
effect of video viewing on intravitreal injection experience

Conditions: Age Related Macular Degeneration; Diabetic Retinopathy; Choroidal Neovascularization; Retinal Vein Occlusion; Cystoid Macular Edema

Summary: study objective the goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing intravitreal anti-vegf injections. key research questions 1. can viewing the procedural video prior to treatment reduce the rate and/or area of subconjunctival hemorrhage? 2. can the video improve the patient experience, specifically by reducing anxiety levels and increasing satisfaction with the treatment process? study design participants will be randomly assigned to either an intervention group, who will watch an educational video explaining the injection procedure, or a control group, who will not view the video. all participants will complete the state-trait anxiety inventory-state (stai-s) questionnaire both before and after treatment to assess changes in anxiety levels.


Eligibility criteria:
inclusion criteria: * patients who are receiving their first intravitreal injection of anti-vegf medication due to retinal diseases * mentally competent, and able to communicate without barriers * willing to voluntarily sign an informed consent form. exclusion criteria: * history of previous eye surgery * best-corrected visual acuity in the better eye worse than 0.3 * the target eye is complicated with neovascular glaucoma.
prognostic value of tumor hypoxia, as measured by 18f-fmiso breath hold pet/ct, in non-small-cell-lung cancer (nsclc) patients

Conditions: Non-Small-Cell-Lung Cancer (NSCLC)

Summary: the purpose of this study is to help researchers investigate if a new imaging agent named 18f-fmiso can predict if patients with lung cancer will respond to standard therapy, as well as whether disease will reoccur in the future. the study will also investigate whether a 18f-fdg pet scan in the middle of radiation treatment can predict if lung cancer will respond to standard therapy. information obtained from this study may help doctors design future studies in which they may target tumor areas that do not respond to therapy or may likely reoccur in the future.


Eligibility criteria:
inclusion criteria: * pathologic confirmation of nsclc at mskcc * no prior treatment for this diagnosis of nsclc * patient to be treated with neoadjuvant chemotherapy (35 patients total) or patient to be treated with definitive rt,sequential chemo-rt, or concurrent chemo-rt (minimum dose of 50 gy in 25 fractions) (25 patients total) * tumor must measure ≥ 2cm on ct * age ≥ 18 years * ability to hold the breath for 10 seconds. * karnofsky performance status ≥ 70% * women of childbearing age must have a negative blood pregnancy test exclusion criteria: * women who are pregnant or breast-feeding * severe diabetes (fasting blood glucose \> 200 mg/dl)

Keywords: pet/ct 18f-fmiso tumor hypoxia 13-186
development of an international covid-19 specific quality of life questionnaire, phase iii. the oslo covid-19 qlq

Conditions: Covid19, Patient Reported Outcome Measures, Quality of Life

Summary: purpose: to develop an international validated patient-reported outcome measure for covid-19 patients according to international guidelines. in this phase iii of the project, the preliminary questionnaire of 80 items will be tested. it has been developed based on literature review and interviews with health care professionals and patients (phase i-ii). in phase iii a patients will fill in the questionnaire followed by interviews on relevance, importance and wording of the questionnaire in phase iii b patients will fill in the questionnaire and an debriefing questionnaire. we will do explorative psychometric analyses.

this project aim to develop an international validated patient-reported outcome measure for covid-19 patients according to international guidelines. the phase i and ii of this development process have been finalized. based on a systematic literature review , interviews with 44 health-care professionals and 52 patients in 6-7 countries a final list of 80 questions, the preliminary oslo covid-19 qlq - pw80 ©, is ready to be tested in the current phase iii of the development process. the objectives of the phase iii are: * in a limited patient group, to check that the items make sense to the target population, that the phrasing and sequence of questions is acceptable, that there are no missing issues and that none of the questions are confusing and/or offensive (phase iiia). * in addition, in a larger patient group, to test hypothesized subscales for psychometric properties including reliability, prevalence and variance (e.g. cronbach's alpha coefficient and correlation-based methods) (phase iiib). the end-product, the international covid-19- specific questionnaire, will be a psychometrically robust patient-reported outcome measure (prom) to assess hrqol in patients with or after covid-19 disease

Eligibility criteria:
inclusion criteria: * patients with verified sars-cov-2 infection (positive test according to local/national standards) * patients with active or previous symptomatic covid-19 disease * in-patients in hospitals and nursing homes or out-patients in hospitals or patients discharged from institutions to their home/covid-19 centres or patients staying at home/covid-19 centres during the course of the disease * patients aged 18 years and older * ability to read and comprehend the process and study documents as judged by the investigator * written informed consent exclusion criteria: * patients in intensive care units (can be recruited after they have been dismissed) * inability to read and comprehend the process and study documents as judged by the investigator
tmvp1-icg mapping in laparoscopic sln detection in cervical cancer

Conditions: Cervical Cancer

Summary: sentinel lymph node (sln) mapping is an acceptable surgical strategy determine whether to perform radical lymphadenectomy in patients with early-stage cervical cancer. investigators aim to determine the validity of this technique with our novel tumor targeted fluorescent tmvp1-icg to increased accuracy of sln mapping.


Eligibility criteria:
inclusion criteria: * at least 18 years of age, married, without childbearing requirements at the time of consent. * figo stage ia1-iib cervical squamous cell cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan. * subject has provided written informed consent. exclusion criteria: * breast-feeding or pregnant * ongoing participation in another clinical trial with an investigational drug with 3 months * own allergy towards icg and/or alcohol * diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases * patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency
trial on tap block after bariatric surgery

Conditions: Morbid Obesity

Summary: patients undergoing bariatric surgery will be divided randomly into two groups: the first will have tap block upon completion of surgery and the second groups will not have tap block.

upon completion of the laparoscopic bariatric procedure to be performed for every patient and just before recovery from general anesthesia, an ultrasound-guided tap block will be conducted in the operative theater by the anesthetist for group i patients whereas group ii will be recovered from anesthesia without having a tap block. the ultrasound probe will be placed on the lateral abdominal wall in the mid-axillary line between the lower costal margin and iliac crest. using ultrasound will allow accurate deposition of the local anesthetic in the correct neurovascular plane. a spinal needle will be advanced using in-plane technique between the aponeurosis of the internal oblique and transversus abdominis muscles. with intermittent aspiration, 20 ml of local anesthetic (0.25% bupivacaine) will be deposited in the tap on each side and seen as a hypoechoic shadow pushing the two layers apart.

Eligibility criteria:
inclusion criteria: * all morbidly obese patients of both genders with bmi \>35 kg/m2 who will be admitted to the general surgery department within the study period to undergo laparoscopic bariatric procedures will be included in this study. bariatric procedures to be performed will comprise lsg, roux en-y- gastric bypass, mini-gastric bypass, gastric plication, and single anastomosis sleeve ileal (sasi) bypass. exclusion criteria: * patients unfit for general anesthesia, patients with secondary obesity due to endocrine disorders, patients with psychiatric disorders, patients with drug abuse or history of opioid intake or chronic pain disorder, patients with contraindication to peripheral nerve block such as allergy to local anesthetics and coagulopathy.
conventional ultrasound for imaging of prostate cancer extent and response in human cancer patients

Conditions: Prostate Cancer

Summary: in this observational study the investigators will undertake imaging studies on men with prostate cancer. the primary hypothesis is that ultrasound spectroscopy could be used to determine the extent of disease inside and outside of the prostate gland in patients with prostate cancer. it is hoped that the changes in ultrasound backscatter parameters obtained before radical prostatectomy could be used to correlate with pathological findings from the prostate specimen after surgery.

this project is an early validation study in human subjects that will use ultrasound imaging and spectroscopy to predict the tumour extent before treatment so that this may allow the most appropriate treatment intervention to be individualised to patients. for examples, patients with evidence of extra-prostatic tissue involvement may be best served with definitive radiation therapy rather than radical prostatectomy as surgery alone in this situation, is not optimum. furthermore, these ultrasound parameters may be used to monitor cell death occurring at various time points during patients' radiation treatment for prostate cancer. the research is exploratory since upon data analysis it will examine the use of different ultrasound parameters as potential markers of pre-treatment tumour extent and cell death, and correlate these with tumour shrinkage and complete pathological response. sensitivity and specificity values for the various ultrasound parameters will be calculated for the different time points used and receiver-operator curves will be generated. from this data the investigators will potentially estimate the best time-points at which to make a prediction about patient response and the best ultrasound-spectroscopy variables to use for this purpose.

Eligibility criteria:
inclusion criteria: * prostate cancer exclusion criteria: * not having radical prostatectomy surgery

Keywords: prostate cancer ultrasound spectroscopy
impact of tavi on cognition, mood and health-related quality of life

Conditions: Cognitive Impairment

Summary: in the proposed study, patients with and without embolic protection devices during transcatheter aortic valve implantation will be repeatedly examined with a comprehensive psychiatric and cognitive test battery over a post-interventional period of 6 months after tavi, with regard to the effects on mood, cognitive performance and health-related quality of life.

the percutaneous aortic valve replacement (tavi, transcatheter aortic valve implantation) enables the implantation of a new biological aortic valve at the beating heart. the procedure is performed under local anaesthesia and is a gold standard in the therapy of aortic stenosis, especially in patients with a too high health risk for cardiovascular surgery. in the proposed study, patients with and without embolic protection devices during tavi will be repeatedly examined with a comprehensive psychiatric and cognitive test battery over a post-interventional period of 6 months after tavi, with regard to the effects on mood, cognitive performance and health-related quality of life.

Eligibility criteria:
inclusion criteria: * written declaration of consent of the study participants to participate in the study after detailed information on the nature, significance, risks and scope of the study. * women and men between the ages of 19 and 90 * clinical indication for tavi intervention * no previous psychiatric illness before tavi * no other serious disease affecting the immune system exclusion criteria: * non-compliance with the inclusion criteria * persons unable to give consent (e.g. dementia, delirium etc.) * magnetic resonance imaging (mr) contraindications * ophthalmological inability to read
assessment of sleep quality of hospitalized patients treated with eeg-guided protection procedures: application in intensive care unit

Conditions: Sleep Quality; Critically Ill Patient; Intensive Care Unit

Summary: sleep of critically ill patients is highly disturbed with a high sleep fragmentation; patients spend most of their sleep in very short sleep episodes, lasting less than 10 minutes. causes of theses sleep alterations are complex including environmental noise (alarms, beepers, conversations...), continuous light, nurse care and repetitive measures of vital parameters. numerous studies have reported a relationship between severe sleep alterations and a prolonged weaning period and mortality. improving sleep quality in critically ill patients is a major challenge to promote icu patient's recovery. a very promising treatment is the application of a nocturnal " quiet-time " during which non urgent care, comfort care, systematic measures of vital parameters are delayed and clustered in order to limit room entries. however, " quiet time " procedures have failed to improve sleep quality to date. a miniaturized medical device recording one eeg channel and embedding an automated sleep scoring algorithm running in real-time was devised. this device (positioned on forehead, and continuously recording noise and light levels) indicates if the patient is awake or asleep using a tablet positioned at doorstep of the room, so that nurses know if patient is sleeping, without entering the room. hypothesis proposes that applying sleep protection procedures (clustering cares, limiting room entries, reducing lights and noise, delaying non urgent care...) when patients are sleeping (= eeg-guided strategies) will increase patients sleep quality. this study will assess the effect of such device on sleep quality in icu patients. this is a "before / after" design. the first group ("control group"), will be recorded but the sleep scoring will not be displayed by the tablet and patient will be expose to standard care. then, procedure will be established collegially with nurses, nurses assistants and doctors. then, the second group ("treated group") will be recorded with the device displaying the status of the patient (asleep/awake) and all caregivers will be asked to follow the established rules ("eeg-guided sleep protection rules")


Eligibility criteria:
inclusion criteria: * adults admitted in medical icu of university hospital of poitiers * un-sedated patients displaying a rass scale between -2 and +1 * intubated or spontaneously breathing patients * patient or family have signed the inform consent exclusion criteria: * patients with a central nervous system disease altering sleep scoring * patients who received drugs (\<24h) modifying significantly eeg and sleep scoring * patients with cutaneous erosion of the scalp